• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Early Corticosteroids in Severe Influenza A/H1N1 Pneumonia and Acute Respiratory Distress Syndrome

tetano

Editor, Senior Moderator
Am J Respir Crit Care Med. 2011 Mar 4. [Epub ahead of print]
Early Corticosteroids in Severe Influenza A/H1N1 Pneumonia and Acute Respiratory Distress Syndrome.

Brun-Buisson C, Richard JC, Mercat A, Thi?baut AC, Brochard L; for the REVA-SRLF A/H1N1v 2009 Registry Group.

R?animation m?dicale, Universit? Paris Est-Cr?teil, CHU Henri Mondor, Cr?teil, France; Pharmacoepidemiology and Infectious Diseases, Inserm U657, Institut Pasteur, Paris, France.
Abstract

Rationale - Despite their controversial role, corticosteroids are often administered to patients with the Adult Respiratory Distress Syndrome (ARDS) secondary to viral pneumonia. We analyzed the outcome of ARDS patients receiving steroids during the recent Influenza A(H1N1) pandemic. Methods - Patients from the French registry of critically ill patients with Influenza A/H1N1v 2009 infection were selected if fulfilling criteria for ARDS, excluding patients having other indication for corticosteroids, or decompensated underlying disease as the primary cause for intensive care unit admission. Survival to hospital discharge was analyzed using Cox regression, accounting for the time to administration of steroids, and after adjustment on the propensity for receiving steroid therapy. Main results - Of 208 patients with ARDS, 83 (39.9 %) received corticosteroids (median initial dose of 270 mg equivalent hydrocortisone per day for a median of 11 days). Steroid therapy was associated with death, both in crude analysis (33.7% vs. 16.8%; hazard ratio
2.4; 95% CI, 1.3-4.3, P = .004) and after propensity score -adjusted analysis (aHR 2.82; 95% CI, 1.5 - 5.4; P= .002), controlling for an admission severity score SAPS 3 > 50, initial administration of vasopressors, and immunodepression. Early therapy (≤3 days of mechanical ventilation) appeared more strongly associated with mortality than late administration. Patients receiving steroids had more acquired pneumonia, and a trend to a longer duration of ventilation. Conclusion - Our study provides no evidence of a beneficial effect of corticosteroids in patients with ARDS secondary to influenza pneumonia, but suggests that very early corticosteroid therapy may be harmful.

PMID: 21471082 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/21471082
 
Back
Top Bottom